ResMed (RMD) Tops Q2 EPS by 22c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to ResMed (RMD) Tops Q2 EPS by 22c, Beats on Revenues
January 23, 2018 12:13 PM EST
ResMed (NYSE: RMD) is seeing buyers bid up shares today, gaining 17% on the session, after the company reported fiscal second quarter earnings per share and revenue figures above consensus, last night after the close.
Analysts on Wall Street responded to the company's... More
January 23, 2018 8:50 AM EST
Northland Capital Markets upgraded ResMed (NYSE: RMD) from Underperform to Market Perform with a price target of $80.00.
Analyst Suraj Kalia comments "While our core thesis on price erosion has been right, with organic GM' down ~700 bps over last 3 yrs & net mgns down ~ 500 bps;... More
January 23, 2018 7:34 AM EST
Needham & Company upgraded ResMed (NYSE: RMD) from Underperform to Hold.
Analyst Mike Matson commented, "RMD's revenue and EPS both significantly beat consensus in F2Q18. Organic revenue growth improved to 11% in F2Q18 from 10% in F1Q18 as RMD saw both stronger... More
January 23, 2018 5:18 AM EST
Barclays raised its price target on ResMed (NYSE: RMD) to $76.00 (from $70.00) while maintaining a Underweight rating.
...
More
